Published in Cancer Weekly, February 1st, 2000
Fentanyl targets (mu)-opioid receptors in the central nervous system and provides analgesia and sedation, according to J. Mercier and colleagues. Side effects associated with the drug are "negligible" compared to those of morphine, they said, noting that fentanyl "is an attractive alternative for cancer pain management."
Mercier et al. described their assay at the 1999 Annual Meeting of the American Association of Pharmaceutical...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.